Kura Oncology's ziftomenib shows 96% complete response in frontline AML and $5.8M in early commercial sales; updated FIT-001 trial data for kidney cancer to be presented at 2026 summit; analysts see significant upside with an average target of $32.45.
The global antibodies market is projected to reach $667.8 billion by 2032 with a 12.9% CAGR, while high throughput antibody production services are expected to grow at 11.2% CAGR through 2033, driven by biopharmaceutical development and monoclonal antibody therapeutics demand.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07629726 |
A Phase 1/2 Study of KK2430 in Participants With Hematologic Neoplasms |
RECRUITING | PHASE1/PHASE2 |
| NCT07623616 |
A Phase 2 Clinical Study of Ziftomenib in Patients With Relapsed or Refractory NPM1-Mutated Acute Myeloid Leukemia |
RECRUITING | PHASE2 |
| NCT06823947 |
Study of KK3910 in Healthy Volunteers and Patients With Essential Hypertension |
RECRUITING | PHASE1 |
| NCT06812104 |
Phase I Clinical Trial of KK2845 in Patients With Relapsed or Refractory Acute Myeloid Leukemia and Other Hematologic Malignancies. |
RECRUITING | PHASE1 |
